Zacks Investment Research | May 08, 2017 09:58PM ET
With the earnings season drawing to a close and the majority of the bigwigs having reported results we can conclude that the earnings picture was positive. As of May 5, 412 S&P 500 members that account for 85.7% of the index’s total market capitalization reported results. Earnings for these companies are up 14.2% year over year on 7.3% higher revenues. Of these, 73.3% beat earnings estimates and 67.7% beat revenue estimates resulting in a blended beat of 52.9%.
Although estimates for the current period have come down, the magnitude has lessened quite a bit as compared to the previous quarters. Results from about 18% of the S&P 500 members are still awaited.
Notably, Medical is one of those sectors which is expected to record growth in the positive territory. As of May 5, 79.6% companies in the Medical sector reported results, putting up a blended beat of 60.5% (the percentage of companies that have beaten both earnings and revenue estimates). Overall the sector has registered 5.9% earnings growth on 6.1% higher revenues.
With these factors in mind, let’s see what awaits these three medical services stocks that are slated to release their first-quarter 2017 results on May 10.
Headquartered in Wilmington, MA, Charles River Laboratories International, Inc. (NYSE:CRL) is an early-stage contract research organization. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions accelerate their research and drug development efforts. The company delivered earnings surprise in the trailing four quarters, with the average beat of 7.63%. The company currently carries a Zacks Rank #3 (Hold) and has an .
Although the rank is favorable, the company’s 0.00% ESP makes surprise prediction difficult. Nevertheless, a long-term expected earnings growth rate of 12.76% raises confidence in the stock. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter .
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.